Systagenix, a supplier of advanced wound dressings, has entered into an agreement with MiMedx Group.

Under the agreement, Systagenix will co-market MiMedx’s EpiFix and will begin its launch during March 2012.

EpiFix is an allograft which is processed through MiMedx’s proprietary Purion Process to optimize wound care and ease of use.

The Purion Process retains the amniotic growth factors inherent in and to placental tissue which promotes cellular ingrowth and enhanced healing.

As part of its distribution agreement, Systagenix will initially conduct the first phase of launch of EpiFix throughout the US, with launches in other countries to follow pending appropriate regulatory approvals.

MiMedx will also continue to sell EpiFix through its existing distributor partners.